Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $5.6667.

Several research firms recently issued reports on IPHA. HC Wainwright lifted their price objective on Innate Pharma from $5.00 to $7.00 and gave the company a "buy" rating in a research note on Monday. Citigroup raised Innate Pharma from a "buy" rating to an "outperform" rating in a report on Tuesday. Weiss Ratings upgraded Innate Pharma from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, June 26th. Finally, UBS Group reissued a "buy" rating on shares of Innate Pharma in a report on Tuesday.

Get Our Latest Stock Report on IPHA

Innate Pharma Stock Performance

IPHA opened at $2.22 on Tuesday. The company has a fifty day moving average price of $1.80 and a 200-day moving average price of $1.67. Innate Pharma has a one year low of $1.17 and a one year high of $2.62.

Institutional Investors Weigh In On Innate Pharma

Hedge funds have recently bought and sold shares of the stock. Millennium Management LLC bought a new position in shares of Innate Pharma in the 4th quarter worth $36,000. OLD Mission Capital LLC bought a new stake in shares of Innate Pharma during the 4th quarter worth $50,000. Finally, Jane Street Group LLC bought a new stake in shares of Innate Pharma during the 4th quarter worth $162,000. 0.16% of the stock is currently owned by institutional investors.

About Innate Pharma

(Get Free Report)

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body's innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company's lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.

Featured Articles

• Five stocks we like better than Innate Pharma
• 3 Overlooked Stocks Analysts Still Like as AI Trades Get Crowded
• China’s Athleisure Boom Is Not Lifting Every Brand Equally
• SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
• 3 Dividend Champion Utilities for a Market That Can't Sit Still

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Innate Pharma Right Now?

Before you consider Innate Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innate Pharma wasn't on the list.

While Innate Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here